This post was originally published on this site Maintenance treatment with Zejula (niraparib) prolongs the time lived without disease worsening in women with newly diagnosed advanced ovarian cancer who are responding to their first-line platinum-based chemotherapy — regardless of mutations in DNA repair genes — a Phase 3 clinical trial has shown. Patients treated with…
This post was originally published on this site The Myeloma Crowd is inviting multiple myeloma patients with psoriasis to join a new study to uncover possible correlations between the two disorders. Study participation is through Myeloma Crowd’s HealthTree platform, where more than 4,500 myeloma patients are currently registered. Launched last fall, the free digital tool…
This post was originally published on this site Bristol-Myers Squibb‘s Opdivo (nivolumab) is superior to chemotherapy for treating patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) that cannot be removed surgically, and who are resistant or intolerant to combination therapy with fluoropyrimidine and platinum-based treatments, the ATTRACTION-3 clinical trial shows. Opdivo demonstrated a…
This post was originally published on this site Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. The findings were presented in a late-breaking presentation titled, “Overall survival (OS) results of the phase III…
This post was originally published on this site Fujifilm SonoSite is collaborating with the Allen Institute of Artificial Intelligence (AI2) Incubator to use artificial intelligence to improve the accuracy of ultrasound images, the standard way to detect ovarian cancer. A developer of bedside and point-of-care ultrasound, Fujifilm SonoSite paired with the AI2 Incubator to use…
This post was originally published on this site IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two trials show. The data, confirming that both trials achieved their primary endpoints, were presented at the 22nd Annual…
This post was originally published on this site Phio Pharmaceuticals and researchers with Helmholtz Zentrum München — the German Research Center for Environmental Health (HMGU) — are working together to develop new approaches to boost the immune system in fighting cancer. The collaboration aims to use Phio’s proprietary self-delivering RNAi (sd-rxRNA) technology to inhibit checkpoint molecules in…
This post was originally published on this site A new injectable flutamide formulation called Liproca Depot is safe, well-tolerated and shows sustained efficacy in untreated men with localized prostate cancer, according to early results of a Phase 2b clinical trial. The LPC-004 Phase 2b trial (NCT03348527) is ongoing at specialist urology clinics in Canada, Lithuania, and…
This post was originally published on this site Ultimately aiming to advance precision medicine, the Multiple Myeloma Research Foundation (MMRF) has officially launched its Direct-to-Patient (DTP) Registry, allowing people with multiple myeloma to securely submit their health data to MMRF CureCloud, the foundation’s data repository. This is the first data repository to gather people’s longitudinal…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Ofev (nintedanib) for the treatment of patients with sarcoidosis and other types of progressive fibrosing interstitial lung diseases (ILDs). The breakthrough designation is given to medications that provide significant advantages over currently available…
